Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Prins, Marloes ^a   Dutta, Ranjan ^a   Baselmans, Bart ^a   Brevé, John J P ^a   Bol, John G J M ^a   Deckard, Sadie A ^a   van der Valk, Paul ^a   Amor, Sandra ^a   Trapp, Bruce D ^a   de Vries, Helga E ^a   Drukarch, Benjamin ^a   van Dam, Anne Marie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Astrocyte; Hippocampus; Microglia; Monocyte chemotactic protein 1; Multiple sclerosis; Proliferation

Indexed keywords

3'-O-(4-BENZOYL)BENZOYLADENOSINE 5'-TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; BROXURIDINE; CCL2 PROTEIN, HUMAN; CCR2 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR2; HLA ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN;

ADULT; AGED; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; GLIA; GRAY MATTER; HIPPOCAMPUS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS; NEWBORN; PATHOLOGY; RAT; WHITE MATTER; WISTAR RAT;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANIMALS; ANIMALS, NEWBORN; BROMODEOXYURIDINE; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; FEMALE; GENE EXPRESSION; GRAY MATTER; HIPPOCAMPUS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; NEUROGLIA; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; RECEPTORS, CCR2; WHITE MATTER;

EID: 84937051907     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-014-0098-6     Document Type: Review

References (83)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med 2000, 372: 1502-1517.
2. Charil A, Zijdenbos AP, Taylor J, Boelman C, Worsley KJ, Evans AC, Dagher A: Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage 2003, 19: 532-544. 10.1016/S1053-8119(03)00117-4
3. De Groot V, Beckerman H, Uitdehaag BM, Hintzen RQ, Minneboo A, Heymans MW, Lankhorst GJ, Polman CH, Bouter LM: Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis. Arch Phys Med Rehabil 2009, 90: 1478-1488. 10.1016/j.apmr.2009.03.018
4. Zackowski KM, Smith SA, Reich DS, Gordon-Lipkin E, Chodkowski BA, Sambandan DR, Shteyman M, Bastian AJ, van Zijl PC, Calabresi PA: Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 2009, 132: 1200-1209. 10.1093/brain/awp032
5. Gilmore CP, Donaldson I, Bö L, Owens T, Lowe J, Evangelou N: Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry 2009, 80: 182-187. 10.1136/jnnp.2008.148767
6. Vercellino M, Plano F, Votta B, Mutani R, Giordana Maria T, Cavalla P: Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005, 64: 1101-1107. 10.1097/01.jnen.0000190067.20935.42
7. Huitinga I, De Groot CJA, Van der Valk P, Kamphorst W, Tilders FJH, Swaab DF: Hypothalamic lesions in multiple sclerosis. J Neuropathol Exp Neurol 2001, 60: 1208-1218.
8. Geurts JJ, Bo L, Roosendaal SD, Hazes T, Daniels R, Barkhof F, Witter MP, Huitinga I, van der Valk P: Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 2007, 66: 819-827. 10.1097/nen.0b013e3181461f54
9. Papadopoulos D, Dukes S, Patel R, Nicholas R, Vora A, Reynolds R: Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol 2009, 19: 238-253. 10.1111/j.1750-3639.2008.00177.x
10. Kutzelnigg A, Faber-Rod JC, Bauer J, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H: Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007, 17: 38-44. 10.1111/j.1750-3639.2006.00041.x
11. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H: Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128: 2705-2712. 10.1093/brain/awh641
12. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47: 707-717. 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
13. Martin R, McFarland HF, McFarlin DE: Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992, 10: 153-187. 10.1146/annurev.iy.10.040192.001101
14. Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23: 683-747. 10.1146/annurev.immunol.23.021704.115707
15. Tran EH, Hoekstra K, Rooijen NV, Dijkstra D, Owens T: Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J Immunol 1998, 161: 3767-3775.
16. Murphy ÁC, Lalor SJ, Lynch MA, Mills KHG: Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010, 24: 641-651. 10.1016/j.bbi.2010.01.014
17. OÁConnor RA, Prendergast CT, Catherine A, Lau CWZ, Leech MD, David C, Anderton SM, Connor RAO, Sabatos CA, Wraith DC: Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental Autoimmune Encephalomyelitis. J Immunol 2008, 181: 3750-3754. 10.4049/jimmunol.181.6.3750
18. Popescu BFG, Bunyan RF, Parisi JE, Ransohoff RM, Lucchinetti CF: A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology 2011, 76: 1705-1710. 10.1212/WNL.0b013e31821a44f1
19. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM, Brück W: Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011, 365: 2188-2197. 10.1056/NEJMoa1100648
20. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD: Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50: 389-400. 10.1002/ana.1123
21. Bö L, Vedeler C, Nyland H, Trapp B, Mörk S: Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003, 9: 323-331. 10.1191/1352458503ms917oa
22. Brink BP, Veerhuis R, Breij ECW, van der Valk P, Dijkstra CD, Bö L: The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005, 64: 147-155.
23. Mahad DJ, Ransohoff RM: The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003, 15: 23-32. 10.1016/S1044-5323(02)00125-2
24. Conductier G, Blondeau N, Guyon A, Nahon J-L, Rovère C: The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010, 224: 93-100. 10.1016/j.jneuroim.2010.05.010
25. Bose S, Cho J: Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. Arch Pharm Res 2013, 36: 1039-1050. 10.1007/s12272-013-0161-z
26. Babcock AA, Kuziel WA, Rivest S, Owens T: Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 2003, 23: 7922-7930.
27. Moreno M, Bannerman P, Ma J, Guo F, Miers L, Soulika AM, Pleasure D: Conditional ablation of astroglial CCL2 Suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. J Neurosci 2014, 34: 8175-8185. 10.1523/JNEUROSCI.1137-14.2014
28. El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed JL, Bruce-Keller AJ, Hauser KF: HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 2006, 53: 132-146. 10.1002/glia.20262
29. Cross AK, Woodroofe MN: Chemokines induce migration and changes in actin polymerization in adult rat brain microglia and a human fetal microglial cell line in vitro. J Neurosci Res 1999, 55: 17-23. 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J
30. Hinojosa AE, Garcia-Bueno B, Leza JC, Madrigal JLM: CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflammation 2011, 8: 77. 10.1186/1742-2094-8-77
31. Yang G, Meng Y, Li W, Yong Y, Fan Z, Ding H, Wei Y, Luo J, Ke Z-J: Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism. Brain Pathol 2011, 21: 279-297. 10.1111/j.1750-3639.2010.00445.x
32. Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y, Rivest S: Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci 2007, 27: 12396-12406. 10.1523/JNEUROSCI.3016-07.2007
33. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FMV: Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011, 14: 1142-1149. 10.1038/nn.2887
34. Brini E, Ruffini F, Bergami A, Brambilla E, Dati G, Greco B, Cirillo R, Proudfoot AE, Comi G, Furlan R, Zaratin P, Martino G: Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss. J Neuroimmunol 2009, 209: 33-39. 10.1016/j.jneuroim.2009.01.022
35. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y: Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 2006, 112: 195-204. 10.1007/s00401-006-0083-7
36. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN: Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998, 84: 238-249. 10.1016/S0165-5728(97)00208-7
37. Van Der Voorn P, Tekstra J, Beelen RH, Tensen CP, van der Valk P, De Groot CJ: Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999, 154: 45-51. 10.1016/S0002-9440(10)65249-2
38. Dutta R, Chang A, Doud MK, Mary K, Kidd GJ, Ribaudo MV, Young EA, Fox RJ, Staugaitis SM, Trapp BD: Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 2011, 69: 445-454. 10.1002/ana.22337
39. Dutta R, Chomyk AM, Chang A, Ribaudo MV, Deckard SA, Doud MK, Edberg DD, Bai B, Li M, Baranzini SE, Fox RJ, Staugaitis SM, Macklin WB, Trapp BD: Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol 2013, 73: 637-645. 10.1002/ana.23860
40. Todorov IT, Werness BA, Wang HQ, Buddharaju LN, Todorova PD, Slocum HK, Brooks JS, Huberman JA: HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues. Lab Invest 1998, 78: 73-78.
41. Bö L, Mörk S, Kong PA, Nyland H, Pardo CA, Trapp BD: Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994, 51: 135-146. 10.1016/0165-5728(94)90075-2
42. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338: 278-285. 10.1056/NEJM199801293380502
43. van der Valk P, De Groot CJ: Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000, 26: 2-10. 10.1046/j.1365-2990.2000.00217.x
44. Ledeboer A, Breve JJP, Wierinckx A, van der Jagt S, Bristow AF, Leysen JE, Tilders FJH, Van Dam A-M: Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells. Eur J Neurosci 2002, 16: 1175-1185. 10.1046/j.1460-9568.2002.02200.x
45. Matute C: Glutamate and ATP signalling in white matter pathology. J Anat 2011, 219: 53-64. 10.1111/j.1469-7580.2010.01339.x
46. Franke H, Verkhratsky A, Burnstock G, Illes P: Pathophysiology of astroglial purinergic signalling. Purinergic Signal 2012, 8: 629-657. 10.1007/s11302-012-9300-0
47. Panenka W, Jijon H, Herx LM, Armstrong JN, Feighan D, Wei T, Yong VW, Ransohoff RM, MacVicar BA: P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. J Neurosci 2001, 21: 7135-7142.
48. Shin N, Baribaud F, Wang K, Yang G, Wynn R, Covington MB, Feldman P, Gallagher KB, Leffet LM, Lo YY, Wang A, Xue C-B, Newton RC, Scherle PA: Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2. Biochem Biophys Res Commun 2009, 387: 251-255. 10.1016/j.bbrc.2009.06.135
49. Brodmerkel CM, Huber R, Covington M, Diamond S, Hall L, Collins R, Leffet L, Gallagher K, Feldman P, Collier P, Stow M, Gu X, Baribaud F, Shin N, Thomas B, Burn T, Hollis G, Yeleswaram S, Solomon K, Friedman S, Wang A, Xue CB, Newton RC, Scherle P, Vaddi K: Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 2005, 175: 5370-5378. 10.4049/jimmunol.175.8.5370
50. Kooi E-J, Prins M, Bajic N, Beliën JA, Gerritsen WH, van Horssen J, Aronica E, van Dam AM, Hoozemans JJ, Francis PT, van der Valk P, Geurts JJ: Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol 2011, 122: 313-322. 10.1007/s00401-011-0849-4
51. Chiaravalloti ND, DeLuca J: Cognitive impairment in multiple sclerosis. Lancet Neurol 2008, 7: 1139-1151. 10.1016/S1474-4422(08)70259-X
52. Rao S, Leo G, Bernardin L, Unverzagt F: Cognitive dysfunction in multiple sclerosis. I. frequency, patterns, and prediction. Neurology 1991, 41: 685-691. 10.1212/WNL.41.5.685
53. Rudick R a, Lee J-C, Nakamura K, Fisher E: Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009, 282: 106-111. 10.1016/j.jns.2008.11.018
54. Fisher E, Lee J-C, Nakamura K, Rudick R a: Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008, 64: 255-265. 10.1002/ana.21436
55. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH: Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008, 64: 247-254. 10.1002/ana.21423
56. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF: MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998, 86: 20-29. 10.1016/S0165-5728(98)00002-2
57. Butt AM, Fern RF, Matute C: Neurotransmitter signaling in white matter. Glia 2014,: 1-18. doi: 10.1002/glia.22674
58. Buschmann JP, Berger K, Awad H, Clarner T, Beyer C, Kipp M: Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. J Mol Neurosci 2012, 48: 66-76. 10.1007/s12031-012-9773-x
59. Matyash V, Kettenmann H: Heterogeneity in astrocyte morphology and physiology. Brain Res Rev 2010, 63: 2-10. 10.1016/j.brainresrev.2009.12.001
60. Hewett JA: Determinants of regional and local diversity within the astroglial lineage of the normal central nervous system. J Neurochem 2009, 110: 1717-1736. 10.1111/j.1471-4159.2009.06288.x
61. Goursaud S, Kozlova EN, Maloteaux J-M, Hermans E: Cultured astrocytes derived from corpus callosum or cortical grey matter show distinct glutamate handling properties. J Neurochem 2009, 108: 1442-1452. 10.1111/j.1471-4159.2009.05889.x
62. Thompson WL, Van Eldik LJ: Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes. Brain Res 2009, 1287: 47-57. 10.1016/j.brainres.2009.06.081
63. Brosnan CF, Cannella B, Battistini L, Raine CS: Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995, 45: 6-11. 10.1212/WNL.45.6_Suppl_6.S16
64. Prins M, Eriksson C, Wierinckx A, Bol JG, Binnekade R, Tilders FJ, Van Dam AM: Interleukin-1β and Interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosis. PLoS One 2013, 8: e83835. 10.1371/journal.pone.0083835
65. Biber K, Neumann H, Inoue K, Boddeke HWGM: Neuronal "On" and "Off" signals control microglia. Trends Neurosci 2007, 30: 596-602. 10.1016/j.tins.2007.08.007
66. Chavarría A, Cárdenas G: Neuronal influence behind the central nervous system regulation of the immune cells. Front Integr Neurosci 2013, 7: 64. 10.3389/fnint.2013.00064
67. Tian L, Rauvala H, Gahmberg CG: Neuronal regulation of immune responses in the central nervous system. Trends Immunol 2009, 30: 91-99. 10.1016/j.it.2008.11.002
68. Roberts TK, Eugenin E a, Lopez L, Romero IA, Weksler BB, Couraud PO, Berman JW: CCL2 disrupts the adherens junction: implications for neuroinflammation. Lab Invest 2012, 92: 1213-1233. 10.1038/labinvest.2012.80
69. Van Horssen J, Brink BP, de Vries HE, van der Valk P, Bö L: The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 2007, 66: 321-328. 10.1097/nen.0b013e318040b2de
70. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN: Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 2000, 108: 192-200. 10.1016/S0165-5728(00)00274-5
71. Eltayeb S, Berg A-L, Lassmann H, Wallström E, Nilsson M, Olsson T, Ericsson-Dahlstrand A, Sunnemark D: Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. J Neuroinflammation 2007, 4: 14. 10.1186/1742-2094-4-14
72. Boddeke EW, Meigel I, Frentzel S, Gourmala NG, Harrison JK, Buttini M, Spleiss O, Gebicke-Härter P: Cultured rat microglia express functional beta-chemokine receptors. J Neuroimmunol 1999, 98: 176-184. 10.1016/S0165-5728(99)00096-X
73. Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R: Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol 2001, 101: 249-255.
74. Gehrmann J, Banati RB, Kreutzberg GW: Microglia in the immune surveillance of the brain: human microglia constitutively express HLA-DR molecules. J Neuroimmunol 1993, 48: 189-198. 10.1016/0165-5728(93)90191-Z
75. Hart AD, Wyttenbach A, Perry VH, Teeling JL: Age related changes in microglial phenotype vary between CNS regions: grey versus white matter differences. Brain Behav Immun 2012, 26: 754-765. 10.1016/j.bbi.2011.11.006
76. Li T, Pang S, Yu Y, Wu X, Guo J, Zhang S: Proliferation of parenchymal microglia is the main source of microgliosis after ischaemic stroke. Brain 2013, 136: 3578-3588. 10.1093/brain/awt287
77. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik V, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999, 103: 807-815. 10.1172/JCI5150
78. Furtado GC, Marcondes MC, Tsai J, Wensky A, Lafaille JJ: Swift entry of myelin-specific T Lymphocytes into the central nervous system in Spontaneous Autoimmune Encephalomyelitis. J Immunol 2008, 181: 4648-4655. 10.4049/jimmunol.181.7.4648
79. McFarland HF, Martin R: Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007, 8: 913-919. 10.1038/ni1507
80. Traugott U, Reinherz EL, Raine CS: Multiple sclerosis. distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 1983, 4: 201-221. 10.1016/0165-5728(83)90036-X
81. Weiss H a, Millward JM, Owens T: CD8+ T cells in inflammatory demyelinating disease. J Neuroimmunol 2007, 191: 79-85. 10.1016/j.jneuroim.2007.09.011
82. Howell OW, Reeves C a, Nicholas R, Carassiti D, Radotra B, Gentleman SM, Serafini B, Aloisi F, Roncaroli F, Magliozzi R, Reynolds R: Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134: 2755-2771. 10.1093/brain/awr182
83. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, Nicholas R, Roncaroli F, Reynolds R: Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012, 135: 2925-2937. 10.1093/brain/aws189